Clinical Trials Logo

Gaucher's Disease Type III clinical trials

View clinical trials related to Gaucher's Disease Type III.

Filter by:
  • None
  • Page 1

NCT ID: NCT05222906 Recruiting - Clinical trials for Gaucher's Disease Type III

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

LEAP2MONO
Start date: April 18, 2022
Phase: Phase 3
Study type: Interventional

This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and <18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.

NCT ID: NCT03485677 Active, not recruiting - Clinical trials for Gaucher's Disease Type III

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

ELIKIDS
Start date: April 11, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to <18 years old). Secondary Objective: Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to <18 years old).